BioPharmSignal logoBioPharmSignal

Biotech News

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsClinical readout

- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH - Phase 1 data published in The New England Journal of Medicine demonstrated a 46% reduction in liver fat in homozygous patients and a well-tolerated safety

Open original release

Related news

ARWRArrowhead Pharmaceuticals2026-07-22 11:30 EST

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

ARWRArrowhead Pharmaceuticals2026-01-27 12:30 EST

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

CRNXCrinetics Pharmaceuticals2026-03-26 20:05 EST

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

KRYSKrystal Biotech2026-01-08 21:01 EST

Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis

CRNXCrinetics Pharmaceuticals2026-01-04 21:00 EST

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

MNPRMonopar2026-06-26 20:05 EST

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

MGTXMeiraGTx2026-04-14 12:30 EST

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

KRYSKrystal Biotech2026-01-07 21:05 EST

Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

TARAProtara Therapeutics2026-04-27 20:05 EST

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

MGTXMeiraGTx2026-04-16 11:00 EST

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

View all latest news

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is an RNA-interference company with deep programs in liver, pulmonary, and rare disease targets.

Recent company news

ARWRArrowhead Pharmaceuticals2026-07-22 11:30 EST

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

ARWRArrowhead Pharmaceuticals2026-07-21 11:30 EST

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

ARWRArrowhead Pharmaceuticals2026-06-22 16:33 EST

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

ARWRArrowhead Pharmaceuticals2026-06-18 11:30 EST

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

ARWRArrowhead Pharmaceuticals2026-06-02 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Stock data

Close
85.53 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States